Valuation Metrics Show Marked Improvement
Albert David Ltd’s current price stands at ₹816.70, up 12.83% on the day from a previous close of ₹723.85, with intraday highs reaching ₹868.60. The stock is trading comfortably above its 52-week low of ₹581.30 and approaching its 52-week high of ₹899.65, signalling renewed investor interest. The company’s price-to-earnings (P/E) ratio has moderated to 20.65, a significant improvement from prior levels that were deemed risky. This P/E is now aligned with a fair valuation grade, indicating that the stock is no longer overvalued relative to its earnings potential.
Complementing the P/E, the price-to-book value (P/BV) ratio is at 1.19, suggesting the stock is trading close to its net asset value, which is attractive for a micro-cap pharmaceutical firm. The enterprise value to EBITDA (EV/EBITDA) ratio of 8.85 further supports the fair valuation stance, especially when compared to peers in the sector who exhibit considerably higher multiples.
Peer Comparison Highlights Relative Attractiveness
When benchmarked against key competitors, Albert David Ltd’s valuation metrics stand out favourably. For instance, NGL Fine Chem and Hester Bios are classified as very expensive with P/E ratios of 44.09 and 38.67 respectively, and EV/EBITDA multiples exceeding 25. Similarly, Shukra Pharma trades at a lofty P/E of 64.99 and EV/EBITDA of 59.42, underscoring the premium valuations in the sector. In contrast, Albert David’s more moderate multiples suggest a valuation discount that could appeal to value-oriented investors.
Other peers such as Venus Remedies and Fredun Pharma also hold fair valuation grades but with higher P/E ratios of 18.01 and 46.87 respectively, and EV/EBITDA multiples of 12.05 and 19.99. This positions Albert David as competitively priced within its peer group, particularly given its micro-cap status and growth prospects.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
Financial Performance and Quality Metrics
Despite the improved valuation, Albert David Ltd’s latest return on capital employed (ROCE) remains negative at -12.53%, reflecting operational challenges and inefficiencies that the company must address to sustain growth. However, the return on equity (ROE) is positive at 5.76%, indicating some shareholder value creation. The dividend yield is modest at 0.61%, which is typical for a company in a growth and restructuring phase.
The company’s EV to capital employed ratio of 1.46 and EV to sales of 0.65 further indicate that the stock is reasonably priced relative to its capital base and revenue generation, reinforcing the fair valuation grade. The PEG ratio of 0.08 is particularly noteworthy, signalling that the stock’s price is low relative to its earnings growth potential, a metric that often attracts growth investors seeking undervalued opportunities.
Stock Performance Versus Market Benchmarks
Albert David Ltd has outperformed the Sensex significantly over recent periods. The stock delivered a 17.94% return over the past week compared to the Sensex’s 0.52%, and a year-to-date return of 10.36% while the Sensex declined by 7.89%. Over the last year, the stock marginally outperformed the benchmark with a 0.46% gain versus a 2.63% decline in the Sensex. However, over longer horizons such as three and five years, the stock’s returns have lagged the Sensex, with 0.04% versus 19.02% and 52.45% versus 44.63% respectively. Over a decade, Albert David Ltd’s 155.14% return trails the Sensex’s 179.57%, reflecting the cyclical and competitive nature of the pharmaceutical sector.
Market Capitalisation and Analyst Ratings
Albert David Ltd is classified as a micro-cap stock, which inherently carries higher volatility and risk but also potential for outsized returns. The recent upgrade in its Mojo Grade from Sell to Hold on 7 August 2026, with a current Mojo Score of 67.0, reflects a more balanced risk-reward profile. This rating change is consistent with the improved valuation parameters and recent price appreciation, signalling cautious optimism among analysts.
Why settle for Albert David Ltd? SwitchER evaluates this Pharmaceuticals & Biotechnology micro-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Outlook and Investment Considerations
Albert David Ltd’s transition from a risky to a fair valuation grade marks a pivotal moment for investors assessing the stock’s price attractiveness. The moderation in P/E and EV/EBITDA multiples relative to peers, combined with a low PEG ratio, suggests the stock is reasonably priced given its growth prospects. However, the negative ROCE and modest dividend yield highlight ongoing operational challenges that could temper near-term upside.
Investors should weigh the company’s micro-cap status and sector volatility against its improved valuation and recent price momentum. The stock’s outperformance relative to the Sensex in the short term is encouraging, but longer-term returns have been mixed. As such, Albert David Ltd currently merits a Hold rating, with potential for upgrade should operational metrics improve and valuation multiples expand further.
In summary, Albert David Ltd offers a more attractive entry point than many of its expensive peers in the Pharmaceuticals & Biotechnology sector. Its fair valuation and improving market sentiment provide a foundation for cautious optimism, making it a stock to watch for investors seeking exposure to micro-cap pharmaceutical opportunities with a balanced risk profile.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
